9月15日,恒瑞医药(600276/01276)发布公告,公司子公司广东恒瑞药有限公司近日收到国家药品监督管理局核准签发的关于注射用瑞卡西单抗的《药物临床试验批准通知书》,将于近期开展III期临床试验。该药物的适应症为颅内动脉粥样硬化性狭窄的成人患者,以降低卒中复发风险。 2026年中期,恒瑞医药实现收入154.56亿元,归母净利润44.65亿元。(文章来源:财中社)
Source Link9月15日,恒瑞医药(600276/01276)发布公告,公司子公司广东恒瑞药有限公司近日收到国家药品监督管理局核准签发的关于注射用瑞卡西单抗的《药物临床试验批准通知书》,将于近期开展III期临床试验。该药物的适应症为颅内动脉粥样硬化性狭窄的成人患者,以降低卒中复发风险。 2026年中期,恒瑞医药实现收入154.56亿元,归母净利润44.65亿元。(文章来源:财中社)
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.